Clinical trials: PMBCL
DLBCL, High-grade B-cell Lymphoma (HGBCL)
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
The purpose of this trial is to measure the following in participants with relapsed and/or refractory B-cell lymphoma who receive epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20): The dose schedule…
- Conditions
- DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL
- Trial name
- EPCORE™ NHL-1 (NCT03625037)
- Testing
- Epcoritamab
- Where
- 85 sites in United States, Australia and 13 more
- Volunteers
- 666 people
- Sponsor
- Genmab
Hodgkin's Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL)
A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)
The primary objective of the study is to evaluate the objective response rate (ORR), by cohort, rrcHL and rrPMBCL, as assessed by the investigator according to Lugano classification criteria 2014 in participants treated with…
- Trial name
- NCT04875195
- Testing
- Pembrolizumab
- Where
- 27 sites in United States, Brazil and 9 more
- Volunteers
- 66 people
- Sponsor
- Merck Sharp & Dohme LLC
B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- NCT06533579
- Testing
- Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Vironexis Biotherapeutics Inc.
Lymphoma, Waldenström Macroglobulinemia (WM)
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma
- Conditions
- Lymphoma, Waldenström Macroglobulinemia (WM), DLBCL - Diffuse Large B Cell Lymphoma, PMBCL
- Trial name
- NCT07249905
- Testing
- MDX2003
- Where
- 2 sites in Australia
- Volunteers
- 180 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma
Pembro Plus CAR T-cell Therapy in R/R in PMBCL
This research study is evaluating the combination of drugs, pembrolizumab with chimeric antigen receptor (CAR) T-cell therapy, as a possible treatment for primary mediastinal B-cell lymphoma that has recurred after prior…
- Conditions
- Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma Refractory, Primary Mediastinal Large B-Cell Lymphoma Recurrent
- Trial name
- NCT05934448
- Testing
- Pembrolizumab, Lymphodepletion Chemotherapy, Chimeric Antigen Receptor (CAR) Therapy Infusion
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Jennifer Crombie, MD
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
This is a Phase 1/2, open-label, single arm, multicohort study to evaluate the safety and efficacy of JCAR017 in pediatric subjects aged ≤ 25 years with CD19+ r/r B-ALL and B-NHL.
- Trial name
- NCT03743246
- Testing
- JCAR017, Lymphodepleting, Fludarabine
- Where
- 19 sites in United States, France and 4 more
- Volunteers
- 21 people
- Sponsor
- Celgene
Non-Hodgkin Lymphoma, T-Cell Lymphoma
Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)
The SCORE-NHL study is a prospective, multi-center, study designed to collect data and biological samples from participants diagnosed with aggressive Stage I to IV non-Hodgkin Lymphoma (NHL).
- Conditions
- Non-Hodgkin Lymphoma, T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, High-Grade B-Cell Lymphoma
- Trial name
- SCORE-NHL (NCT07750886)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Natera, Inc.
Relapsed/Refractory Large B-cell Lymphoma (LBCL), Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
This study is aimed to explored the safety and efficacy of 7×19-THEMIS CAR-T cell therapy for large B-cell lymphoma and to conduct an exploratory comparison of the 3-month objective response rate (ORR) and complete remission rate…
- Conditions
- Relapsed/Refractory Large B-cell Lymphoma (LBCL), Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), Transforming Follicular Lymphoma (tFL)
- Trial name
- NCT07788118
- Testing
- 7×19-THEMIS CAR-T cells
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Diffuse Low Grade B-Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Italian Observational Study on CAR-T Therapy for Lymphoma
The goal of this observational study on chimeric antigen receptor T-cell therapy is to monitor the feasibility, efficacy, toxicity and biomarkers in a real life setting.
- Conditions
- Diffuse Low Grade B-Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Mantle Cell Lymphoma, Follicular Lymphoma
- Trial name
- CART-SIE (NCT06339255)
- Where
- Italy
- Volunteers
- 5,300 people
- Sponsor
- Paolo Corradini
Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Primary Mediastinal Large B-cell Lymphoma With CNS Involvement
This is a retrospective, multicenter study focused on patients with a known diagnosis of PMLBCL which experienced a CNS relapse during the course of their disease to obtain information about the clinical characteristics, the…
- Trial name
- NCT06024694
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- IRCCS San Raffaele
B Cell Lymphoma (BCL)
Multi-CAR-T Cells Targeting B Cell Lymphomas
This study aims to evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting B cell surface molecules including CD19 and alternative CARTs as booster and…
- Trial name
- NCT04429438
- Testing
- 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Diffuse Large B Cell Lymphoma (DLBCL), Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Axatilimab + CAR-T for High-Risk Lymphoma
Axatilimab + CAR-T in High-Risk Lymphoma
- Conditions
- Diffuse Large B Cell Lymphoma (DLBCL), Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma (HGBCL), High-Grade B-Cell Lymphoma, Nos
- Trial name
- NCT07638982
- Testing
- Axatilimab
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Northside Hospital, Inc.
Cardiovascular Diseases, B-cell Acute Lymphoblastic Leukemia
CAR T Cell Therapy Related Cardiovascular Outcomes
This will be a cohort study of all patients receiving Cluster of Differentiation 19 (CD19)-specific CAR T cell therapy for relapsed/refractory B cell haematological malignancies.
- Conditions
- Cardiovascular Diseases, B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent
- Trial name
- CARTCO (NCT05130489)
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- University College London Hospitals
Primary Mediastinal Large B Cell Lymphoma, EBV-Positive DLBCL, Nos
Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL
The study is to investigate the safety and efficacy of Zanubrutinib combined with Tislelizumab in the treatment of relapsed/refractory primary mediastinal large B-cell lymphoma and Epstein-Barr Virus-positive diffuse large B-cell…
- Trial name
- NCT04705129
- Testing
- Zanubrutinib, Tislelizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital
Non Hodgkin Lymphoma, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
- Conditions
- Non Hodgkin Lymphoma, Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma
- Trial name
- NCT06116110
- Testing
- Long-term Follow-Up
- Where
- 11 sites in United States
- Volunteers
- 150 people
- Sponsor
- Miltenyi Biomedicine GmbH
Primary Mediastinal Large B Cell Lymphoma
A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment
The purpose of this multi-center, single arm, phase Ⅱ clinical trail is to evaluate the efficacy and toxicity of sintilimab combined with R-CHOP regimen as first-line treatment for primary mediastinal large B-cell Lymphoma (PMBCL)
- Trial name
- NCT06412068
- Testing
- Combined anti-PD-1 and R-CHOP
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
This study is being done to evaluate the safety, tolerability and effectiveness of Oral CG-806 for the treatment of patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas…
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
- Trial name
- NCT03893682
- Testing
- CG-806
- Where
- 30 sites in United States
- Volunteers
- 36 people
- Sponsor
- Aptose Biosciences Inc.
Large B Cell Lymphoma, LBCL
Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy
This Phase 2, multicenter, open-label study will evaluate the safety and efficacy of a single infusion of Prizloncel, an anti-CD19/CD20 chimeric antigen receptor T cells following lymphodepleting chemotherapy in participants with…
- Conditions
- Large B Cell Lymphoma, LBCL, Diffuse Large B Cell Lymphoma (DLBCL), Relapse Diffuse Large B Cell Lymphoma
- Trial name
- NCT07875413
- Testing
- Prizloncabtagene Autoleucel
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- AbelZeta Inc.
Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma
Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients
This is a multi-center, phase I/II study to determine the efficacy and safety of CRC01 in adult patients with relapsed or refractory large B-cell lymphoma and B-cell Acute Lymphoblastic Leukemia.
- Conditions
- Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
- Trial name
- NCT04836507
- Testing
- CRC01, Fludarabine, Cyclophosphamide
- Where
- 2 sites in South Korea
- Volunteers
- 91 people
- Sponsor
- Curocell Inc.
B-Cell Leukemia, Non-Hodgkin's Lymphoma
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
This is a phase I dose-finding trial of an autologous CD22 targeting chimeric antigen receptor (CAR)-T cell product, called CLIC-2201, for participants with relapsed/refractory B cell malignancies.
- Conditions
- B-Cell Leukemia, Non-Hodgkin's Lymphoma, B-cell Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- NCT06208735
- Testing
- CLIC-2201
- Where
- 7 sites in Canada
- Volunteers
- 24 people
- Sponsor
- British Columbia Cancer Agency